Navigation Links
Synthetic Biologics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
Date:9/3/2013

ROCKVILLE, Md., Sept. 3, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE-MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  Mr. Riley is scheduled to present at 12:05 p.m. (Eastern Time) on Monday, September 9, 2013 at the Millennium Broadway Hotel in New York City.

A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the internet at http://wsw.com/webcast/rrshq23/SYN. After the presentation, a replay will be archived and accessible for 30 days at the same website.

Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, will be available to participate in one-on-one meetings with attendees who are registered for the conference. If you are an institutional investor, and would like to attend the Company's presentation, please register for the Rodman & Renshaw conference using the following link www.rodm.com. Once your registration is confirmed, you will be prompted to log into the conference website and may request a one-on-one meeting with the Company.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE-MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update
2. Synthetic Biologics to Report Second Quarter 2013 Financial Results
3. Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
4. Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability
5. Synthetic Biologics to Present at OneMedForum New York 2013
6. New England Biolabs supports iGEM synthetic biology competition
7. Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference
8. Intrexon Organizes Around New Synthetic Biology Markets
9. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
10. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
11. Express Genes by Eurofins MWG Operon Offers 4 Day Delivery of Synthetic Genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... DELHI , February 8, 2016 ... Invictus Oncology Private Limited, an innovation-driven oncology company ... effective and less toxic, today announced that chairman ... Tata, has invested in the company as part ... financing round, joining existing investors Navam Capital and ...
(Date:2/8/2016)... ... , ... Bulk food product inspection systems are specifically designed ... the production process. Despite frequently inspecting loose product prior to packaging, product inspection ... sacks of dry powders. , Mettler-Toledo Product Inspection's brand-new white paper entitled "Improving ...
(Date:2/8/2016)... 8, 2016 --> ... the "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today ... Chlamydia trachomatis (CT) test to be launched on the Company,s ... (98/79/EC), the CT test is now cleared for sale within ... The launch of the io® CT test signals a ...
(Date:2/5/2016)... SAN DIEGO , Feb. 5, 2016 ... the region,s trusted information source for community, health and ... San Diego) will integrate to enhance care coordination ... people to the services they need and to better ... to improve care.   San Diego ...
Breaking Biology Technology:
(Date:1/25/2016)... BLUE BELL, Pa. , Jan. 25, 2016   Unisys ... facial recognition system at John F. Kennedy (JFK) International Airport, ... and Border Protection (CBP) identify imposters attempting to enter ... or do not belong to them. pilot testing ... rolled out initially at three terminals at JFK during January 2016. ...
(Date:1/22/2016)... DUBLIN , Jan. 22, 2016 /PRNewswire/ ... announced the addition of the "Global ... report to their offering. --> ... of the "Global Biometrics Market in ... offering. --> Research and ...
(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):